IP Roundup: Theranos, Mitsubishi Chemical Medience, Tokyo Medical and Dental University, Affymetrix | GenomeWeb

Theranos of Palo Alto, Calif., has received US Patent No. 8,202,697, "Medical device for analyte monitoring and drug delivery." An ingestible, implantable or wearable medical device is claimed. The device consists of a microarray that contains a bioactive agent capable of interacting with a disease marker biological analyte, and a reservoir that contains therapeutic agents and is capable of releasing the therapeutic agents from the device.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.